Heparin News and Research

RSS

Heparin, a highly-sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. It can also be used to form an inner anticoagulant surface on various experimental and medical devices such as test tubes and renal dialysis machines. Pharmaceutical grade heparin is derived from mucosal tissues of slaughtered meat animals such as porcine (pig) intestine or bovine (cow) lung.

Researchers develop tools to identify patients at risk of medication harm

A University of Queensland research collaboration will look at reducing the risk of harm from medication for inpatients and those leaving hospital to return home.

4 Sep 2023

Anticoagulation after primary PCI does not prevent adverse outcomes in STEMI patients

Anticoagulation after primary percutaneous coronary intervention (PCI) does not prevent adverse outcomes in patients with ST-segment elevation myocardial infarction (STEMI), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

29 Aug 2023

New DNA-based anticoagulant could treat heparin-induced thrombocytopenia

Various medical circumstances, including heart attacks and extreme cases of COVID-19, necessitate the use of anticoagulants, medicines that prevent blood clots

21 Aug 2023

Adenovirus infection linked to rare blood clotting disorder

Platelets, or thrombocytes, are specialized cellular fragments that form blood clots when we get scrapes and traumatic injuries. Viral infections, autoimmune disease, and other conditions can cause platelet levels to drop throughout the body, termed thrombocytopenia.

10 Aug 2023

Study detects biomarker changes nearly 30 years before symptom onset of Alzheimer’s disease

A new paper has shown how Alzheimer’s disease pathology comes into being over a period of almost three decades.

10 Aug 2023

EPFL scientists develop an innovative method for reconstructing Tau fibrils

EPFL scientists have developed ClearTau, an innovative method and platform for reconstructing aggregates of the protein Tau found in Alzheimer's disease and other neurodegenerative diseases.

4 Jul 2023

New CHEST guideline offers recommendations to manage arterial thrombosis and thromboembolism in COVID-19

The American College of Chest Physicians (CHEST) recently released a new clinical guideline on antithrombotic therapy in arterial thrombosis and thromboembolism in COVID-19.

29 Jun 2023

Experts identify a novel fucosylated heparan sulfate from the midgut gland of the Japanese scallop

Glycosaminoglycans (GAGs), including chondroitin sulfate (CS), heparan sulfate (HS), heparin, and hyaluronan are linear and acidic polysaccharides found in the extracellular matrix of all animal tissues. GAGs are widely used as functional ingredients in health products, pharmaceuticals, and cosmetics, and are prepared from biological samples such as shark cartilage and porcine intestinal mucosa. Consequently, the demand for new sources of GAGs is ever-present. For example, the supply source of the anticoagulant heparin-;generally prepared from porcine intestinal mucosa in China-;was threatened by African swine fever in 2018.

15 Jun 2023

Gut bacteria toxins: A hidden trigger for Parkinson's disease?

Gut dysfunction and the presence of lipopolysaccharide (LPS) endotoxins contribute to the pathogenesis of Parkinson's disease (PD), leading to neuroinflammation and neurodegeneration. Modulating the gut microbiome and reducing LPS levels may hold potential as treatment strategies for PD.

24 May 2023

Researchers develop novel bio-inspired molecules to enhance bone regeneration

People's ability to regenerate bones declines with age and is further decreased by diseases such as osteoporosis.

28 Apr 2023

Groundbreaking discovery could pave the way for safer and more effective blood thinners

Safer and more effective blood thinners could be on the way following a groundbreaking discovery by researchers at UBC and the University of Michigan, published today in Nature Communications.

26 Apr 2023

Non-critically ill hospitalized Covid-19 patients could substantially benefit from a higher dose of blood-thinners

Giving noncritically ill patients hospitalized for COVID-19 a higher dose of blood-thinning medication than usual did not significantly reduce the combined risk of death from any cause, need for treatment in an intensive-care unit, a confirmed blood clot or a stroke at 30 days, according to the results of the FREEDOM-COVID trial presented at the American College of Cardiology's Annual Scientific Session Together With the World Congress of Cardiology.

6 Mar 2023

Anti-heparin antibodies develop in patients with spontaneous heparin-induced thrombocytopenia without heparin exposure

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Spontaneous heparin-induced thrombocytopenia is a pro-thrombotic syndrome in which anti-heparin antibodies develop without heparin exposure.

17 Feb 2023

Researchers report two unusual COVID-19-related arrhythmic cases in children

Researchers explored the association between cardiac arrhythmias in children and COVID-19 infection.

8 Feb 2023

The impact of viral infections on the human endocrine system

Researchers briefly outlined how viral infections trigger endocrinopathies in humans.

3 Feb 2023

Research offers a cost-effectiveness analysis of anticoagulant drugs for cancer-associated thrombosis

Newly published research out of the University of Cincinnati and the University of California-Davis shows that direct oral anticoagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin for treating cancer-associated thrombosis.

4 Jan 2023

Cost-effectiveness analysis of four interventions for treatment of cancer-associated thrombosis

A cost-effectiveness analysis comparing direct oral anticoagulants (DOACs) to low-molecular-weight heparin (LMWH) found that DOACs are both more medically effective and cost-effective than LMWH when treating cancer-associated thrombosis (CAT).

27 Dec 2022

Direct oral anticoagulants more effective and cost-effective for treating cancer-associated thrombosis

Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati shows that direct oral anti-coagulant (DOAC) drugs are more effective and are more cost-effective than low molecular weight heparin (LMWH) for treating cancer-associated thrombosis (CAT).

27 Dec 2022

What are the long-term outcomes of critical COVID-19 patients?

Researchers assessed the long-term outcomes of critically ill coronavirus disease 2019 (COVID-19) patients.

21 Dec 2022

Natural material derived from seaweed can help improve outcomes after heart bypass surgery

Researchers are using a natural material derived from seaweed to promote vascular cell growth, prevent blood clots and improve the performance of synthetic vascular grafts used in heart bypass surgery.

5 Dec 2022